Garcia VC, Mansfield C, Leach C, Pierce A, Smith JC, Afonso M. Patient and caregiver preferences for hemophilia treatments: a discrete-choice experiment. Haemophilia. 2024 Mar;30(2):375-87. doi: 10.1111/hae.14928
Poonawalla IB, Bowe AT, Tindal MC, Meah YA, Schwab P. A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists. Diabetes Res Clin Pract. 2021 May;175:108800. doi: 10.1016/j.diabres.2021.108800
Graz H, D'Souza VK, Alderson DEC, Graz M. Diabetes-related amputations create considerable public health burden in the UK. Diabetes Res Clin Pract. 2018 Jan;135:158-65. doi: 10.1016/j.diabres.2017.10.030
Raghunathan K, Layton JB, Ohnuma T, Shaw AD. Observational research using propensity scores. Adv Chronic Kidney Dis. 2016 Nov;23(6):367-72. doi: 10.1053/j.ackd.2016.11.010
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
Lawton J, Kirkham J, Rankin D, Barnard K, Cooper CL, Taylor C, Heller S, Elliott J, Basarir H, REPOSE group. Perceptions and experiences of using automated bolus advisors amongst people with type 1 diabetes: a longitudinal qualitative investigation. Diabetes Res Clin Pract. 2014 Dec;106(3):443-50. doi: 10.1016/j.diabres.2014.09.011
DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014 Jul;20(4):e296-303. doi: 10.1111/hae.12459
Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia. 2011 May 1;17(3):476-82.
Lee LJ, Fahrbach JL, Nelson LM, McLeod LD, Martin SA, Sun P, Weinstock RS. Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the DURABLE trial. Diabetes Res Clin Pract. 2010 Aug 1;89(2):157-66.
Hoerger TJ, Zhang P, Segel JE, Gregg EW, Venkat Narayan KM, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Diabetes Res Clin Pract. 2009 Dec 1;86(3):225-32.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.
Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.
Donatti C, Wild D, Horblyuk R, Beusterien KM, Anderson R, Arondekar B, DiBenedetti DB. Psychometric evaluation of the satisfaction with Oral Anti-Diabetic Agent Scale. Diabetes Res Clin Pract. 2008 Apr;80(1):108-13.